Table 2.

Adverse Events Observed in ≥10% of Ruxolitinib-Treated Patients.

Adverse Event	Ruxolitinib (N=155) % of patients		Placebo (N=151) % of patients
	All Grades	Grade 3 or 4	All Grades	Grade 3 or 4
Nonhematologic
Fatigue	25.2	5.2	33.8	6.6
Diarrhea	23.2	1.9	21.2	0
Peripheral edema	18.7	0	22.5	1.3
Ecchymosis	18.7	0	9.3	0
Dyspnea	17.4	1.3	17.2	4.0
Dizziness	14.8	0.6	6.6	0
Nausea	14.8	0	19.2	0.7
Headache	14.8	0	5.3	0
Constipation	12.9	0	11.9	0
Vomiting	12.3	0.6	9.9	0.7
Pain in extremity	12.3	1.3	9.9	0
Insomnia	11.6	0	9.9	0
Arthralgia	11.0	1.9	8.6	0.7
Pyrexia	11.0	0.6	7.3	0.7
Abdominal pain	10.3	2.6	41.1	11.3
Hematologic (laboratory values)*
Hemoglobin	96.1	45.2	86.8	19.2
Platelets	69.7	12.9	30.5	1.3
Neutrophils	18.7	7.1	4.0	2.0

^*Patients are included at their worst grade on study regardless of whether this represents a change from their baseline.